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Cyclooxygenase-2 (COX-2) is an inducible enzyme that drives in-
flammation and is the therapeutic target for widely used non-
steroidal antiinflammatory drugs (NSAIDs). However, COX-2 is
also constitutively expressed, in the absence of overt inflammation,
with a specific tissue distribution that includes the kidney, gastroin-
testinal tract, brain, and thymus. Constitutive COX-2 expression is
therapeutically important because NSAIDs cause cardiovascular and
renal side effects in otherwise healthy individuals. These side effects
are now of major concern globally. However, the pathways driving
constitutive COX-2 expression remain poorly understood. Here we
show that in the kidney and other sites, constitutive COX-2 expres-
sion is a sterile response, independent of commensal microorganisms
and not associated with activity of the inflammatory transcription
factor NF-κB. Instead, COX-2 expression in the kidney but not other
regions colocalized with nuclear factor of activated T cells (NFAT)
transcription factor activity and was sensitive to inhibition of calci-
neurin-dependent NFAT activation. However, calcineurin/NFAT reg-
ulation did not contribute to constitutive expression elsewhere or to
inflammatory COX-2 induction at any site. These data address the
mechanisms driving constitutive COX-2 and suggest that by target-
ing transcription it may be possible to develop antiinflammatory
therapies that spare the constitutive expression necessary for nor-
mal homeostatic functions, including those important to the
cardiovascular-renal system.
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Cyclooxygenase (COX) converts arachidonic acid to prosta-noids, which include prostaglandins (PGs), prostacyclin, and
thromboxane. Prostanoids are important mediators that regulate
diverse functions in the cardiovascular, gastrointestinal, urogenital,
and nervous systems, as well as playing critical roles in immunity,
inflammation and resolution of inflammation. There are two COX
isoforms: COX-1 and COX-2. COX-1 is a constitutive, house-
keeping enzyme that is ubiquitously expressed and is responsible
for prostanoid production in most tissues (1). In contrast, COX-2 is
an inducible enzyme, expressed at sites of inflammation, infection,
and cancer (2) that generates prostanoids that drive disease path-
ogenesis. COX-2 is the therapeutic target for antiinflammatory
drugs, including ibuprofen, naproxen, and diclofenac, as well
as newer COX-2 selective inhibitors such as Celebrex (celecoxib;
Pfizer); collectively these drugs are known as nonsteroidal anti-
inflammatory drugs (NSAIDs). NSAIDs are among the most
commonly taken antiinflammatory pain medications globally;
they are the first-line therapy for patients with arthritis and can
prevent cancer. However, COX-2 is also expressed constitutively in
areas not associated with inflammation, including the brain, thymus,
gut, and kidney (3). Constitutive COX-2 is increasingly recognized to
play a major role in homeostatic function, for example, having de-
fined roles in the developing brain (4) and adult kidney (5) and gut
(6). As such, inhibition of constitutive COX-2 by NSAIDs causes
adverse effects that limit their use. Upper gastrointestinal side ef-
fects associated with NSAID use are due to the combined inhibition
of COX-1 and -2 (6) but are relatively well managed by the use of
NSAIDs selective for COX-2 and concurrent use of proton pump
inhibitor drugs. However, NSAID-associated cardiovascular and
renal side effects remain a major clinical concern. This concern has
resulted in a series of regulatory events including (i) the withdrawal
of the blockbuster drug Vioxx (rofecoxib; Merck) in 2004, (ii) the
introduction of “black box” warnings on some NSAIDs from 2005
and on all drugs in this class since 2015, (iii) the withdrawal of
Onsenal (celecoxib; Pfizer) for the prevention of cancer in 2011,
and (iv) the reclassification of the over-the-counter medication
diclofenac as prescription only in 2015 (United Kingdom). Now the
fear of cardiovascular events caused by NSAIDs has resulted in the
cautious prescribing of COX-2–selective drugs (7) in favor of older
style medications that are more toxic to the gut and a failure to
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realize the full clinical potential of NSAIDs in the prevention of
cancer (8). Because side effects associated with NSAIDs are a result
of inhibition of constitutive COX-2, at sites important to homeo-
static regulation, it is imperative that we establish what drives ex-
pression at these sites in the absence and presence of inflammation.
Our recent work demonstrated that, in the kidney, constitutive
COX-2 expression in the renal medulla works as a powerful tran-
scriptional brake on hundreds of genes, including those regulating
cardiovascular pathways (5). Constitutive COX-2 in the kidney and
other sites occurs in the absence of inflammation, suggesting that
distinct mechanisms exist whereby COX-2 can be regulated in two
very different settings: constitutively in health and in an inducible
manner in disease. Detailed studies identifying and comparing the
pathways responsible for constitutive vs. inducible COX-2 expres-
sion have not yet been reported, but are of critical importance to
both our understanding of COX-2 biology and the search for better,
safer ways to therapeutically target the COX-2 pathway.
COX-2 gene [Ptgs2 (prostaglandin-endoperoxide synthase 2)]
transcription is driven by a number of pathways, with binding sites
in the promoter region for several transcription factor complexes
including, most notably, NF-κB (9), and, of direct relevance to
renal COX-2, nuclear factor of activated T cells (NFAT) (10). For
both NF-κB and NFAT transcription pathways, bacteria, including
some forms of commensal bacteria (11), are key driving factors.
These observations suggest that the microbiome could be a source
of direct stimuli for constitutive COX-2 expression, particularly in
the gut and other barrier tissues. Indeed, studies using germ-free
mice have demonstrated that commensal bacteria influence a
range of pathological processes impacting on the cardiovascular
(12) and nervous systems (13).
Here, we directly address the pathways by which COX-2 is
constitutively expressed, under noninflammatory conditions,
across a range of tissues and, for comparison, in the same tissues
where inflammation has been robustly induced using LPS. Based
on the rationale above, we focused our studies of constitutive
COX-2 expression on the role of (i) commensal bacterial, (ii)
NF-κB, and (iii) NFAT.
Results and Discussion
Although COX-1 is considered the archetypal constitutive form
of the enzyme and is widely expressed throughout the body,
COX-2 is also expressed constitutively, but restricted to discrete
regions (3). Here we confirm and extend our previous observa-
tions (3), using luciferase COX-2 reporter mice (Fig. 1) and
quantitative PCR (qPCR) (SI Appendix, Fig. S1) to compare
constitutive COX-2 expression throughout the body. As we
reported previously (3), COX-2 expression is essentially absent
in cardiovascular tissues, including the heart and aorta, but is
highly expressed in the renal medulla and renal pelvis, the gas-
trointestinal tract, lung, thymus, and brain, with the cerebral
cortex showing the highest expression (Fig. 1). Here we also
show that the COX-2 gene is highly expressed in the bladder
(Fig. 1), which may be important in understanding the contri-
bution of COX-2 to urinary prostanoid metabolites, which are
commonly used indicators of their circulating counterparts (14).
Because COX-2 is readily induced by inflammatory insults
such as bacterial LPS, we studied the possibility that commensal
bacteria might regulate constitutive COX-2 expression. Germ-
free mice are devoid of a microbiome, including gut bacteria. We
found that these mice display gastrointestinal abnormalities, re-
duced body weight, and reduced basal levels of the IFN response
cytokine CXCL10 (SI Appendix, Fig. S2). Our observations are
consistent with those previously reported for germ-free mice,
which have developmental constraints in the gut and altered
immune function (15). Despite these differences, constitutive
COX-2 in the renal medulla, cerebral cortex, and gastrointestinal
tract was not affected in germ-free mice (Fig. 2 and SI Appendix,
Table S1). However, constitutive expression in the spleen and
thymus was increased (Fig. 2 and SI Appendix, Table S1). Ele-
vated COX-2 expression in the spleen and thymus may reflect
altered T-cell function in these mice (15). Germ-free mice
responded like control mice to pathogenic LPS derived from
Escherichia coli with increased expression of COX-2 and the
related inducible iNOS gene [Nos2 (nitric oxide synthase 2, in-
ducible)] in the spleen and elevated plasma levels of CXCL10 (SI
Appendix, Fig. S2). These observations allow us to effectively rule
Fig. 1. Tissue distribution of luciferase activity driven from the endogenous Cox2 gene. Basal expression from the endogenous Cox2 gene promoter was
visualized by bioluminescent imaging of tissue from Cox2fLuc/+ mice (A). Quantification of images, as maximal luminescence from each tissue, demonstrates
high expression in the renal medulla, gastrointestinal (GI) tract, and selected regions of the brain and thymus (B). Data are means ± SEM; n = 8.









out products of bacterial or other microbial drivers for consti-
tutive COX-2 expression.
If not through pathogenic stimuli, then how is constitutive
COX-2 expression regulated? Multiple transcriptional pathways
have been implicated in driving inducible COX-2 expression.
Growth factors predominantly act through the mitogen-activated
protein kinase-signaling cascades to induce COX-2 in proliferating
cells. During inflammation, the two best-studied transcriptional
pathways driving inducible COX-2 expression are NFAT and NF-κB
(16). We focused on these inflammation-associated transcriptional
pathways and sought to establish whether they also play a role in
sterile, constitutive COX-2 expression. Using specific NFAT (17) and
NF-κB (18) luciferase reporter mice to map transcription factor ac-
tivity, we found colocalization in the kidney for NFAT-driven tran-
scriptional activity and endogenous constitutive COX-2 promoter-
driven reporter gene expression (Fig. 3). Constitutive NFAT activity,
like constitutive COX-2 expression, was essentially absent in the renal
cortex but abundant in the renal medulla and renal pelvis regions
(Fig. 3). In these regions, there was a striking overlap between NFAT
activity and COX-2 expression. Additional, strong NFAT activity was
Fig. 2. Constitutive COX-2 mRNA expression in germ-free mice. Basal expression of COX-2 mRNA, measured by qPCR, was not different between control mice
and germ-free mice in the renal medulla (A), cerebral cortex (B), or colon (C), and was increased in the thymus (D) and spleen (E) of germ-free animals. Data
are means ± SEM; n = 12. *P < 0.05 by unpaired t test.
Fig. 3. Distribution of constitutive luciferase activ-
ity driven from NFAT and NF-κB transcriptional re-
sponse elements. Constitutive activity of NFAT and
NF-κB and expression from the endogenous Cox2
gene promoter (COX-2), visualized using biolumi-
nescent imaging of tissue from NFAT, NF-κB, and
COX-2 luciferase reporter mice (A). Quantification
demonstrates that constitutive NFAT activity is
greatest in the renal medulla/pelvis, colon, and
cerebellum (B) and that constitutive NF-κB activity is
greatest in the heart, bladder, gastrointestinal tract,
liver, as well as barrier and inflammatory tissues (C).
Comparison of these patterns with those for con-
stitutive COX-2 expression shows strong overlap
between NFAT and COX-2 in the renal medulla and
between NF-κB and COX-2 in the gastrointestinal tract
and thymus (D). Heat map gradients from black
(baseline) to red (maximal tissue) are individually scaled
for each target. Data are means ± SEM; n = 10–16.
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present in the distal renal pelvis where COX-2 is present but less
abundant than the inner medulla (Fig. 3), suggesting complex regu-
lation of COX-2 by NFAT in the kidney. In contrast to the pattern of
NFAT activity, NF-κB activity was detected only at a low level in all
studied regions of the kidney and did not spatially map to COX-2
expression (Fig. 3). In other regions of high COX-2 expression, no-
tably in the brain and the gut, NFAT activity was relatively high, but
the distribution did not match that of COX-2 expression (Fig. 3).
Constitutive NF-κB activity was surprisingly high in the heart (Fig. 3),
with some activity present in the aorta. However, as described above,
these cardiovascular structures do not constitutively express COX-2.
NF-κB transcriptional activity was also high in the bladder, lung,
thymus, and gut tissues, which do express constitutive COX-2 (Fig. 3).
Although spleen, skin, and liver showed among the highest levels of
constitutive NF-κB activity, these organs do not highly express COX-
2, indicating that the presence of NF-κB (or NFAT) activity alone in
these organs is not sufficient to drive COX-2 gene expression, and
additional layers of regulation must exist.
Although mapping transcription factor activity provided a com-
pelling case for NFAT, but not NF-κB, as the transcriptional driver
of COX-2 expression in the kidney, colocalization does not prove
cause and effect. To test the roles of the NFAT and NF-κB re-
quirement in constitutive COX-2 expression in the kidney (and
elsewhere), we used a pharmacological approach; examining the
modulatory effects of cyclosporin A, which inhibits calcineurin-
dependent NFAT activation (19), and BMS-345541, which inhibits
IκB kinase-2–dependent NF-κB activation (20). COX-2 expression
(Fig. 4 and SI Appendix, Table S2) was significantly reduced in the
renal medulla and renal pelvis of mice treated with cyclosporin A
but not in mice treated with BMS-345541 (Fig. 4 and SI Appendix,
Table S2), consistent with a lack of constitutive NF-κB activation in
this area (Figs. 3 and 4). The selective effect of cyclosporin A on
COX-2 observed in luciferase reporter mice was confirmed at the
level of mRNA in renal medulla (control, 1.00 ± 0.59; BMS, 1.29 ±
0.66; P = 0.75, n = 6; cyclosporin A; Fig. 5 and SI Appendix, Table
S3). To demonstrate the functional significance of these changes in
COX-2 expression, we measured prostaglandin formation in the
isolated renal medulla and found a profound reduction in COX-2–
dependent PGE2 formation in mice treated with cyclosporin A (SI
Appendix, Table S3). The inability of BMS-345541 to influence
constitutive COX-2 expression was not due to inactivity of the drug/
dosing regime as BMS-345541 reduced renal NF-κB activity and
LPS-induced plasma TNFα accumulation (Fig. 5). Further, in
agreement with an NFAT, rather than an NF-κB transcriptional
pathway, constitutive COX-2 expression was not inhibited by
dexamethasone (SI Appendix, Fig. S3). For all other regions
studied, neither cyclosporin A nor BMS-345541 altered consti-
tutive expression from the COX-2 promoter (Fig. 4 and SI Ap-
pendix, Table S2), suggesting constitutive COX-2 at these sites is
not driven by classical inflammatory COX-2 pathways or com-
mensal microorganisms, but rather through distinct mechanisms.
In the gut, for example, COX-2 may be driven through pro-
liferative pathways such as MAPK as a byproduct of continual
epithelial proliferation. Alternatively, in the brain, COX-2 may
be constitutively induced through neuronal activity and associ-
ated transcriptional pathways including cAMP response ele-
ment-binding protein (CREB), whose pattern of constitutive
activity bears striking similarity to that of COX-2 (21), and thy-
roid-transcription factor-1 (TTF-1), which has been linked to
COX-2 in certain brain regions (22).
Cyclosporin A is used clinically as an immunosuppressant. In
patients, as well as animal models, it has been associated with
renal toxicity (23), which may reflect its ability of suppress renal
Fig. 4. Effect of NFAT and NF-κB pathway inhibitors on luciferase activity driven from the endogenous Cox2 gene. Constitutive COX-2 expression, measured using
bioluminescent imaging of tissue from Cox2fLuc/+mice, was reduced by cyclosporin A (CsA; 4 d; 20 mg/kg per day; s.c.) an inhibitor of calcineurin/NFAT activation in
the renal medulla and pelvis (A) but not the renal cortex (A), colon (B), brain (C), thymus (D), or lung (E). BMS-345541 (BMS; 4 d; 10 mg/kg per day; i.v.), an inhibitor
of NF-κB activation had no effect in any studied tissue (A–E). Data are means ± SEM; n = 4. *P < 0.05 by one-way ANOVA with Dunnett’s posttest.
Fig. 5. Effect of CsA and BMS-345541 on renal NF-κB activity and LPS-induced
cytokine levels. Treatment of NF-κB-luc mice with BMS-345541 (BMS; 4 d;
10mg/kg per day; i.v.) reduced renal medulla NF-κB activity (A), whereas treatment
with CsA (4 d; 20 mg/kg per day; s.c.) had no effect (A). BMS but not CsA treat-
ment suppressed LPS (10 mg/kg; 4 h)-induced plasma levels of TNFα (B). Data are
means ± SEM; n = 3–6. *P < 0.05 by one-way ANOVA with Dunnett’s posttest.









COX-2. Nonetheless, cyclosporin A at the dose and duration used
here did not alter serum creatinine levels (Fig. 6), suggesting its
effects on COX-2 expression in our study were not a result of
fundamentally compromised renal function. Cyclosporin A also
did not cause nonspecific effects on gene transcription, because it
did not alter expression of iNOS or constitutive COX-1 [Ptgs1
(prostaglandin-endoperoxide synthase 1)] (Fig. 6). In the renal
medulla, COX-2 is highly localized to interstitial fibroblasts, where
it colocalizes with the cell selective marker tenascin C (24).
Cyclosporin A suppression of renal COX-2 expression was not due
to loss of interstitial fibroblasts, because cyclosporin A did not
alter tenascin C levels (Fig. 6).
NFAT has five isoforms, four (NFATc1–c4) of which are typically
dependent on calcineurin for activation and thus sensitive to cyclo-
sporin A (25). Cyclosporin A can also affect transcriptional function
of the fifth isoform, NFAT5, by inhibiting its translocation to the
nucleus (26), although NFAT5 can also be activated through
cyclosporin A-insensitive pathways. In the renal medulla, mRNAs
for all NFAT isoforms (NFATc1–c4, NFAT5) were detectable by
qPCR (Ct values < 30; SI Appendix, Fig. S4). However, it is currently
beyond the scope of this study to establish the isoform(s) of NFAT
that regulate constitutive COX-2 expression, due to development
defects (including to the kidney) (27, 28) arising from specific
NFAT deletions, redundancy among NFAT isoforms, and a lack
of isoform-specific pharmacological tools. We suggest that iden-
tification of the NFAT isoform responsible for constitutive COX-2
expression will only be possible with the development of mice
lacking the multiple NFAT isoforms, specifically in the kidney
and/or specific inhibitors. Nevertheless, our initial objective was to
establish the transcriptional pathway by which COX-2 is expressed
constitutively in the renal medulla and our data establish NFAT as
the predominate mechanism.
Last, we sought to determine whether NFAT also drives ex-
pression of COX-2 in the kidney, and other structures, at times of
overt inflammation. We regard this as an important issue; if we are
able to dissociate constitutive COX-2 expression in the kidney from
inducible COX-2 at sites of inflammation, we will create future
therapeutic opportunities to target inflammation-driven COX-2
expression (at the transcriptional level) while sparing the kidney,
thereby avoiding NSAID cardio-renal side effects. As we have
shown previously (29), in mice treated with LPS, COX-2 is readily
induced in the renal medulla, the spleen (Fig. 7), and a full range of
other tissues (SI Appendix, Table S4). In direct contrast to results
seen for constitutive expression, cyclosporin A-sensitive NFAT
pathways did not drive inflammatory COX-2 expression in the renal
medulla or, indeed, in any tissue tested (SI Appendix, Table S4).
Summary and Conclusions
COX-2 is expressed constitutively in discrete tissue regions, in-
cluding the renal medulla. This constitutive COX-2 expression is
not mediated by host pathogenic stimuli because no effect was
seen on levels in tissues from germ-free mice. NFAT, but not
NF-κB, transcription regulates constitutive COX-2 expression in
the renal medulla; however, neither transcriptional pathway
contributes to constitutive expression in other tissues. This in-
dicates that constitutive COX-2 across different tissues is driven
through distinct, locally relevant pathways (e.g., NFAT, MAPK,
CREB, TTF-1) rather than a broad regulation through classical
inflammatory pathways/commensal microorganisms. In addition,
the transcriptional regulation of constitutive COX-2 in the renal
medulla is distinct from pathways that drive inflammatory COX-2,
which is the therapeutic target of NSAIDs.
These findings address a fundamental and long-standing question
in the field of COX-2 biology and have direct relevance to the
therapeutic targeting of COX-2 to spare activity and expression at
sites of homeostatic control and thereby avoid the side effects
Fig. 6. Effect of CsA on renal gene expression and function. Constitutive COX-2 mRNA expression, measured using qPCR, was reduced in the renal medulla
(A) by treatment with CsA (4 d; 20 mg/kg per day; s.c.). CsA treatment also reduced COX-2–dependent PGE2 formation by isolated renal medulla (B). In WT
mice, CsA treatment did not alter constitutive expression of iNOS (C), COX-1 (D), or the renal interstitial cell marker tenascin C (E) and did not alter plasma
levels of creatinine (F). Data are means ± SEM; n = 3–6. *P < 0.05 by unpaired t test.
Fig. 7. Effect of CsA on luciferase activity driven from the endogenous Cox2
gene in LPS-treated mice. LPS (10 mg/kg; 4 h; i.p.) increased COX-2 expression
in renal medulla and spleen, visualized using bioluminescent imaging of tissue
from Cox2fLuc/+mice (A). Quantification of imaging data indicated no effect of
CsA treatment (4 d; 20 mg/kg per day; s.c.) on LPS-induced COX-2 expression in
either the renal medulla (B) or spleen (C). This result was confirmed by qPCR
analysis of renal medulla (D) and spleen (E) from WT mice. Data are means ±
SEM; n = 3–6. *For all panels, effect of CsA, P > 0.05 by unpaired t test.
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associated with NSAIDs. First, we showed that cyclosporin A se-
lectively suppresses COX-2 expression in the kidney without altering
constitutive COX-2 at other sites. We previously suggested the
kidney to be a major driver of NSAID cardiovascular side effects,
where constitutive COX-2 in the renal medulla produces profound
regulation of cardioprotective gene networks (5). As such, cyclo-
sporin A may provide an important tool to probe the contribution of
renal COX-2 to the cardiovascular side effects attributed to NSAIDs
use. In this regard, it is interesting to note that in animal models (30)
and in humans (31), cyclosporin A, as with COX-2 inhibitors, in-
creases circulating levels of the naturally occurring eNOS inhibitor
ADMA; a mechanism that we recently highlighted as relevant to the
cardiovascular side effects associated with NSAIDs (5). Second and
perhaps more importantly, our observations lay groundwork for the
idea that targeting COX-2 at the transcriptional level could disso-
ciate antiinflammatory benefit of NSAIDs from their cardio-renal
side effects. Although this will require a more complete un-
derstanding of the drivers of COX-2 in inflammation and cancer,
these data indicate that, in the future, any therapies directed at
COX-2 transcriptional pathways that spare NFAT signaling would
avoid the renal pathways responsible for driving the cardiovascular
side effects that currently limit NSAID use.
Materials and Methods
Additional methodological information can be found in SI Appendix.
Animals. Studies were performed on male and female 8- to 10-wk-old COX-2
luciferase knock-in reporter mice (Cox2fLuc/+) (32), transgenic luciferase re-
porter mice for NFAT (NFAT-luc) (17) or NF-κB (NFκB-RE-luc) activity (18),
germ-line COX-1 KO mice (Cox1−/−) (33), or WT C57BL/6 mice (Charles River/
Taconic) raised under normal or germ-free conditions (34) (Farncombe
Gnotobiotic Unit). All procedures were carried out in accordance with local
rules and ethical review by the University of California Los Angeles Animal
Research Committee (Protocol no.: 1999-066-32; Cox2fLuc experiments), An-
imal Care Committee of the Faculty of Health Sciences at McMaster Uni-
versity (NFκB-RE-luc and germ-free experiments), Malmö/Lund Animal Care
and Use Committee (Permit no.: M29-12; NFAT-luc experiments), or the
Imperial College Ethical Review Panel (PPL 70/7013; all other experiments).
Mice were treated with cyclosporin A (20 mg/kg; Novartis), BMS-345541
(10 mg/kg; Sigma), dexamethasone (3 mg/kg; Organon), or vehicle for 4 d.
In some cases, inflammation was induced by LPS (10 mg/kg; from E. coli
serotype 055:B5; Sigma) 4 h before euthanasia.
Bioluminescent Imaging. Ex vivo bioluminescent imaging of tissue from lu-
ciferase reporter strains was performed as we previously described (3) using
an IVIS imaging system (Xenogen).
qPCR. RNA was extracted from tissue homogenates using a silica bead kit (Life
Technologies) and reverse transcribed (Life Technologies), andgeneexpressionwas
measured with TaqMan (Life Technologies) or SYBRGreen assays (Bio-Rad). Data
were analyzed using the comparative Ct method, with reference to housekeeping
genes [18S and Gapdh (glyceraldehyde 3-phosphate dehydrogenase)].
PGE2 Synthesis Bioassay. COX-2–dependent prostaglandin synthesis was
measured in tissue segments from Cox1−/− mice stimulated with A23187
calcium ionophore (50 μM; Sigma) for 30 min at 37 °C. PGE2 accumulation
was measured by immunoassay (Cisbio).
Plasma Cytokine and Creatinine Measurement. Plasma levels of CXCL10 (R&D
Systems) and TNFα (Meso Scale Discovery) were measured by immunoassay. Cre-
atinine was measured by a commercial biochemistry service (IDEXX Laboratories).
Statistics and Data Analysis. Data were analyzed using Prism 6.0 software
(GraphPad Software) and are presented as mean ± SE. Details of statistical
tests are given in figure legends.
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